Jaguar Animal Health (NASDAQ:JAGX – Get Free Report) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare Jaguar Animal Health to similar businesses based on the strength of its valuation, dividends, risk, earnings, analyst recommendations, institutional ownership and profitability.
Risk and Volatility
Jaguar Animal Health has a beta of -0.09, suggesting that its share price is 109% less volatile than the S&P 500. Comparatively, Jaguar Animal Health’s peers have a beta of -0.04, suggesting that their average share price is 104% less volatile than the S&P 500.
Profitability
This table compares Jaguar Animal Health and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Jaguar Animal Health | -187.88% | N/A | -131.45% |
| Jaguar Animal Health Competitors | -2,398.26% | -203.62% | -15.08% |
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Jaguar Animal Health and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Jaguar Animal Health | 1 | 0 | 0 | 0 | 1.00 |
| Jaguar Animal Health Competitors | 7845 | 13798 | 25818 | 1039 | 2.41 |
As a group, “Pharmaceuticals” companies have a potential upside of 24.32%. Given Jaguar Animal Health’s peers stronger consensus rating and higher possible upside, analysts clearly believe Jaguar Animal Health has less favorable growth aspects than its peers.
Valuation and Earnings
This table compares Jaguar Animal Health and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Jaguar Animal Health | $11.51 million | -$53.43 million | -0.00 |
| Jaguar Animal Health Competitors | $18.73 billion | $3.24 billion | 559.17 |
Jaguar Animal Health’s peers have higher revenue and earnings than Jaguar Animal Health. Jaguar Animal Health is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
12.0% of Jaguar Animal Health shares are held by institutional investors. Comparatively, 32.7% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.1% of Jaguar Animal Health shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Jaguar Animal Health peers beat Jaguar Animal Health on 11 of the 13 factors compared.
Jaguar Animal Health Company Profile
Jaguar Health, Inc., formerly Jaguar Animal Health, develops prescription medicines for gastrointestinal disorders in humans and animals. The company’s research has focused on plant-derived compounds, including crofelemer, which is derived from the Croton lechleri tree. Jaguar’s animal-health product Canalevia-CA1 received FDA conditional approval for the treatment of chemotherapy-induced diarrhea in dogs. The company also develops and commercializes crofelemer-based medicines for human gastrointestinal conditions.
Receive News & Ratings for Jaguar Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jaguar Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.
